Rocket Pharmaceuticals (RCKT) Depreciation & Amortization (CF) (2015 - 2026)

Rocket Pharmaceuticals has disclosed Depreciation & Amortization (CF) across 12 years of filings, most recently posting $1.6 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $1.6 million, down 34.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.0 million (up 0.9% YoY), and the FY2025 annual result was $8.9 million, up 22.85% from the prior year.
• Depreciation & Amortization (CF) came in at $1.6 million for Q1 2026 at Rocket Pharmaceuticals, down from $1.7 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.7 million in Q3 2025 to a low of -$2.1 million in Q4 2022.
• The 5-year median for Depreciation & Amortization (CF) is $1.6 million (2026), against an average of $1.4 million.
• Across the five-year window, Depreciation & Amortization (CF) plunged 298.0% in 2022 and soared 167.02% in 2023, its largest moves.
• Rocket Pharmaceuticals' Depreciation & Amortization (CF) stood at -$2.1 million in 2022, then jumped by 167.02% to $1.4 million in 2023, then surged by 30.52% to $1.8 million in 2024, then decreased by 7.9% to $1.7 million in 2025, then decreased by 4.17% to $1.6 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.6 million (Q1 2026), $1.7 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.